CombinatoRx (CRXX) Collaborator Fovea Acquired by Sanofi-Aventis
CombinatoRx, Incorporated (NASDAQ: CRXX) announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis.
A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.
CombinatoRx Interim President and CEO, Robert Forrester, said, "We are pleased to see that a CombinatoRx-derived combination drug candidate has been recognized as a key asset in the proposed acquisition of Fovea, our ophthalmic collaborator."
A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.
CombinatoRx Interim President and CEO, Robert Forrester, said, "We are pleased to see that a CombinatoRx-derived combination drug candidate has been recognized as a key asset in the proposed acquisition of Fovea, our ophthalmic collaborator."
You May Also Be Interested In
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary Endpoint; to Move Forward with End of Phase Meeting
- Shares of Edgar Online (EDGR) are up more than 45% following $1.09/share bid from RR Donnelley (RRD)
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
